← All candidates
3 insider filings on record.
11 filings on record.
VTVTvTv Therapeutics Inc.
NasdaqCM · Healthcare · $127.95M
$32.80
+0.00% today
3 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what VTVT ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$127.95M
Float
2.2M
55% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
3.5
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$54.33 avg target
+65.7% vs today · 6 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26$1.65 act+$1.44
Q4 '25−$0.58 act+$0.51
Q3 '25−$1.08 act−$0.10
Q2 '25−$0.92 act−$0.10
Coverage
vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen NextSimply Wall St. · 05-17vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be SustainableZacks · 05-15Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?Zacks · 04-20Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a BetZacks · 04-02
The file stays open
11 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice